The prevalence of proarrhythmic events during moricizine therapy and their relationship to ventricular function.

Abstract

The prevalence of proarrhythmic events during moricizine therapy was studied in 144 patients who were treated for symptomatic ventricular tachycardia or ventricular fibrillation. The overall incidence of proarrhythmia was 15.3%. (Twenty-two patients exhibited 23 events.) Ventricular fibrillation occurred in six patients (which led to three deaths), incessant ventricular tachycardia occurred in seven, and new sustained ventricular tachycardia in four. Patients with proarrhythmia had significantly lower left ventricular ejection fraction (24% vs 39%; p less than 0.0001), higher prevalence of congestive heart failure (68% vs 36%; p less than 0.005), and higher incidence of previous proarrhythmia (45% vs 9%; p less than 0.0001). No significant difference between the two groups was found in respect to age, arrhythmia at presentation, underlying heart disease, moricizine dose, or concomitant drug therapy.

• Authors: O Tschaidse, T B Graboys, B Lown, S Lampert, S Ravid
• Journal: American heart journal (Am Heart J) Vol. 124 Issue 4 Pg. 912-6 (Oct 1992) ISSN: 0002-8703 [Print] United States
• PMID: 1529903 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Moricizine

Topics

• Drug Evaluation
• Electrocardiography
• Female
• Humans
• Incidence
• Male
• Middle Aged
• Moricizine (adverse effects, therapeutic use)
• Prevalence
• Risk Factors
• Stroke Volume (physiology)
• Tachycardia (chemically induced, drug therapy, epidemiology)
• Ventricular Fibrillation (chemically induced, drug therapy, epidemiology)
• Ventricular Function (physiology)